Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients
with advanced solid tumors and varying degrees of renal impairment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02301117.
This is a Phase 1, open-label study to evaluate the safety, tolerability, and
pharmacokinetics of TAS-102 in patients with advanced solid tumors with varying degrees
of renal impairment. The study is conducted in 2 parts: the Pharmacokinetic Part (Cycle
1) and the Extension Part (Cycles 2 and beyond). Patients may continue to receive
treatment with TAS-102 during the study extension part only after completion of the
Pharmacokinetic Part.
Lead OrganizationTaiho Pharmaceutical Company Limited
